A型肉毒毒素在神经科应用进展
Advances in Application of Botulinum Toxin Type A in Neurology
DOI: 10.12677/ACM.2022.123241, PDF,   
作者: 秦亚辉, 黄 月*：郑州大学人民医院，河南省人民医院神经内科，河南 郑州
关键词: A型肉毒毒素；眼睑痉挛；面肌痉挛；肌张力障碍；Botulinum Toxin Type A； Blepharospasm； Hemifacial Spasm； Dystonia
摘要: A型肉毒毒素因其疗效明确、注射方式便捷、可重复注射、性价比高等诸多优势，近些年被广泛应用于神经科肌肉痉挛疾病的管理及治疗中，但在真实世界临床应用过程中，仍然存在诸多亟待解决的问题，这给神经科医生对疾病的管理和优化诊治策略带来新的机遇和挑战，本文通过综合阐述A型肉毒毒素在临床应用中的现状分析及面临的困惑及不足，提高了对肉毒毒素临床应用的认识，为未来更好地在神经科领域的临床应用，制定个体化的诊疗策略奠定了良好的理论基础。
Abstract: Botulinum toxin type A has been widely used in the management and treatment of neuromuscular spasm diseases in recent years due to its clear curative effect, convenient injection method, repeatable injection, and high cost performance. However, in the process of clinical application in the real world, there are still many urgent problems to be solved, which bring new opportunities and challenges to neurologists for disease management and optimization of diagnosis and treatment strategies. This article comprehensively expounds the current analysis of the clinical application of botulinum toxin type A, as well as the puzzles and shortcomings it faces, and raises the understanding of the clinical application of botulinum toxin. It has laid a good theoretical foundation for better clinical application in the field of neurology in the future, and the formulation of individualized diagnosis and treatment strategies.
文章引用：秦亚辉, 黄月. A型肉毒毒素在神经科应用进展[J]. 临床医学进展, 2022, 12(3): 1679-1685. https://doi.org/10.12677/ACM.2022.123241

参考文献

[1] Skorochod, R., Nesher, R., Nesher, G. and Gronovich, Y. (2021) Ophthalmic Adverse Events Following Facial Injections of Botulinum Toxin A: A Systemic Literature Review. Journal of Cosmetic Dermatology, 20, 2409-2413. [Google Scholar] [CrossRef] [PubMed]
[2] Langenberg, J., Noort, D., Snyder, D. and Foster, K. (2018) AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins (Basel), 10, 535. [Google Scholar] [CrossRef] [PubMed]
[3] Bellows, S. and Jankovic, J. (2019) Immunogenicity Associated with Botulinum Toxin Treatment. Toxins (Basel), 11, 491. [Google Scholar] [CrossRef] [PubMed]
[4] Gutierrez, S.A.S., Yu, J.R.T., Yalung, P.M. and Jamora, R.D.G. (2021) Real-World Experience with Botulinum Toxin A for the Treatment of Hemifacial Spasm: A Study of 1138 Injections. Clinical Neurology and Neurosurgery, 205, Article ID: 106632. [Google Scholar] [CrossRef] [PubMed]
[5] Mitsikostas, D.D., Dekundy, A., Hanschmann, A., Althaus, M., Scheschonka, A., Pagan, F. and Jankovic, J. (2021) Duration and Onset of Effect of IncobotulinumtoxinA for the Treatment of Blepharospasm in Botulinum Toxin-Naïve Subjects. Current Medical Research and Opinion, 37, 1761-1768. [Google Scholar] [CrossRef] [PubMed]
[6] Argyriou, A.A., Mitsikostas, D.D., Mantovani, E., Vikelis, M. and Tamburin, S. (2021) Beyond Chronic Migraine: A Systematic Review and Expert Opinion on the Off-Label Use of Botulinum Neurotoxin Type-A in Other Primary Headache Disorders. Expert Review of Neurotherapeutics, 21, 923-944. [Google Scholar] [CrossRef] [PubMed]
[7] Marsili, L., Bologna, M., Jankovic, J. and Colosimo, C. (2021) Long-Term Efficacy and Safety of Botulinum Toxin Treatment for Cervical Dystonia: A Critical Reappraisal. Expert Opinion on Drug Safety, 20, 695-705. [Google Scholar] [CrossRef] [PubMed]
[8] Dressler, D., Pan, L., Su, J., Teng, F. and Jin, L. (2021) Lantox—The Chinese Botulinum Toxin Drug-Complete English Bibliography and Comprehensive Formalised Literature Review. Toxins (Basel), 13, 370. [Google Scholar] [CrossRef] [PubMed]
[9] Dressler, D. and Benecke, R. (2007) Pharmacology of Therapeutic Botulinum Toxin Preparations. Disability and Rehabilitation, 29, 1761-1768. [Google Scholar] [CrossRef] [PubMed]
[10] Abrams, S.B. and Hallett, M. (2013) Clinical Utility of Different Botulinum Neurotoxin Preparations. Toxicon, 67, 81-86. [Google Scholar] [CrossRef] [PubMed]
[11] Satriyasa, B.K. (2019) Botulinum Toxin (Botox) A for Reducing the Appearance of Facial Wrinkles: A Literature Review of Clinical Use and Pharmacological Aspect. Clinical, Cosmetic and Investigational Dermatology, 12, 223-228. [Google Scholar] [CrossRef] 
[12] Carr, W.W., Jain, N. and Sublett, J.W. (2021) Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications. Advances in Therapy, 38, 5046-5064. [Google Scholar] [CrossRef] [PubMed]
[13] Jankovic, J. (2017) Botulinum Toxin: State of the Art. Movement Disorders, 32, 1131-1138. [Google Scholar] [CrossRef] [PubMed]
[14] Rouientan, A., Alizadeh Otaghvar, H., Mahmoudvand, H. and Tizmaghz, A. (2019) Rare Complication of Botox Injection: A Case Report. World Journal of Plastic Surgery, 8, 116-119. [Google Scholar] [CrossRef] [PubMed]
[15] Dressler, D. and Bigalke, H. (2017) Immunological Aspects of Botulinum Toxin Therapy. Expert Review of Neurotherapeutics, 17, 487-494. [Google Scholar] [CrossRef] [PubMed]
[16] Dressler, D. and Saberi, F.A. (2017) Safety of Botulinum Toxin Short Interval Therapy Using IncobotulinumtoxinA. Journal of Neural Transmission (Vienna), 124, 437-440. [Google Scholar] [CrossRef] [PubMed]
[17] Ray, J.C., Hutton, E.J. and Matharu, M. (2021) OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy. Journal of Clinical Medicine, 10, 2898. [Google Scholar] [CrossRef] [PubMed]
[18] Klein, A.W. (2002) Complications and Adverse Reactions with the Use of Botulinum Toxin. Disease-A-Month, 48, 336-356. [Google Scholar] [CrossRef] [PubMed]
[19] Nestor, M., Ablon, G. and Pickett, A. (2017) Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration. Aesthetic Surgery Journal, 37, S20-S31. [Google Scholar] [CrossRef] [PubMed]
[20] Herrero-Infante, Y., Rodríguez-Sanz, A., Máñez-Miró, J. and Vivancos-Matellano, F. (2021) Hemifacial Spasm through the Last Three Decades: From Etiology to Efficacy and Safety of Long-Term Botulinum Toxin Treatment. Clinical Neurology and Neurosurgery, 203, Article ID: 106555. [Google Scholar] [CrossRef] [PubMed]
[21] Xu, L., Xu, W., Wang, J., Chong, Y., Liang, W. and Jiang, C. (2020) Persistent Abnormal Muscle Response after Microvascular Decompression for Hemifacial Spasm. Scientific Reports, 10, Article No. 18484. [Google Scholar] [CrossRef] [PubMed]
[22] Nielsen, V.K. (1985) Electrophysiology of the Facial Nerve in Hemifacial Spasm: Ectopic/Ephaptic Excitation. Muscle Nerve, 8, 545-555. [Google Scholar] [CrossRef] [PubMed]
[23] Wang, A. and Jankovic, J. (1998) Hemifacial Spasm: Clinical Findings and Treatment. Muscle Nerve, 21, 1740-1747. [Google Scholar] [CrossRef] 
[24] 肉毒毒素治疗应用专家组, 中华医学会神经病学分会帕金森病及运动障碍学组. 中国肉毒毒素治疗应用专家共识[J]. 中华神经科杂志, 2018, 51(10): 779-786.
[25] Liu, J., Li, F., Wu, G., Liu, B., Zhou, J., Fan, C., Jiao, F., Wang, D., Wu, G., Song, H. and Liu, R. (2021) Long-Term Retrospective Analysis of Re-do Microvascular Decompression in Patients with Hemifacial Spasm. Frontiers in Neurology, 12, Article ID: 687945. [Google Scholar] [CrossRef] [PubMed]
[26] Wu, F., Wei, P., Wang, G., Wu, C., Hu, Y. and Hu, J. (2021) Roles of Preoperative Anxiety and Depression in the Outcomes of Microvascular Decompression in Hemifacial Spasm for Adolescent Patients. Medicine (Baltimore), 100, e26831. [Google Scholar] [CrossRef] 
[27] Batisti, J.P., Kleinfelder, A.D., Galli, N.B., Moro, A., Munhoz, R.P. and Teive, H.A. (2017) Treatment of Hemifacial Spasm with Botulinum Toxin Type A: Effective, Long Lasting and Well Tolerated. Arquivos de Neuro-Psiquiatria, 75, 87-91. [Google Scholar] [CrossRef] [PubMed]
[28] Kenney, C. and Jankovic, J. (2008) Botulinum Toxin in the Treatment of Blepharospasm and Hemifacial Spasm. Journal of Neural Transmission, 115, 585-591. [Google Scholar] [CrossRef] [PubMed]
[29] Dover, J.S., Monheit, G., Greener, M. and Pickett, A. (2018) Botulinum Toxin in Aesthetic Medicine: Myths and Realities. Dermatologic Surgery, 44, 249-260. [Google Scholar] [CrossRef] 
[30] Sorgun, M.H., Yilmaz, R., Akin, Y.A., Mercan, F.N. and Akbostanci, M.C. (2015) Botulinum Toxin Injections for the Treatment of Hemifacial Spasm over 16 Years. Journal of Clinical Neuroscience, 22, 1319-1325. [Google Scholar] [CrossRef] [PubMed]
[31] Jankovic, J., Kenney, C., Grafe, S., Goertelmeyer, R. and Comes, G. (2009) Relationship between Various Clinical Outcome Assessments in Patients with Blepharospasm. Movement Disorders, 24, 407-413. [Google Scholar] [CrossRef] [PubMed]
[32] Roggenkämper, P., Jost, W.H., Bihari, K., Comes, G. and Grafe, S. (2006) Efficacy and Safety of a New Botulinum Toxin Type A Free of Complexing Proteins in the Treatment of Blepharospasm. Journal of Neural Transmission (Vienna), 113, 303-312. [Google Scholar] [CrossRef] [PubMed]
[33] 中华医学会神经病学分会, 中华医学会神经病学分会帕金森病及运动障碍学组. 肌张力障碍诊断中国专家共识[J]. 中华神经科杂志, 2020, 53(1): 8-12.
[34] Simpson, D.M., Hallett, M., Ashman, E.J., Comella, C.L., Green, M.W., Gronseth, G.S., Armstrong, M.J., Gloss, D., Potrebic, S., Jankovic, J., Karp, B.P., Naumann, M., So, Y.T. and Yablon, S.A. (2016) Practice Guideline Update Summary: Botulinum Neurotoxin for the Treatment of Blepharospasm, Cervical Dystonia, Adult Spasticity, and Headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 86, 1818-1826. [Google Scholar] [CrossRef] 
[35] Pandey, S. and Sharma, S. (2017) Meige’s Syndrome: History, Epidemiology, Clinical Features, Pathogenesis and Treatment. Journal of the Neurological Sciences, 372, 162-170. [Google Scholar] [CrossRef] [PubMed]
[36] Gamain, J., Herr, T., Fleischmann, R., Stenner, A., Vollmer, M., Willert, C., Veit, B., Lehnert, B., Mueller, J.U., Steigerwald, F., Tost, F. and Kronenbuerger, M. (2021) Smell and Taste in Idiopathic Blepharospasm. Journal of Neural Transmission (Vienna), 128, 1215-1224. [Google Scholar] [CrossRef] [PubMed]
[37] Albanese, A., Asmus, F., Bhatia, K.P., Elia, A.E., Elibol, B., Filippini, G., Gasser, T., Krauss, J.K., Nardocci, N., Newton, A. and Valls-Solé, J. (2011) EFNS Guidelines on Diagnosis and Treatment of Primary Dystonias. European Journal of Neurology, 18, 5-18. [Google Scholar] [CrossRef] [PubMed]
[38] Jankovic, J., Comella, C., Hanschmann, A. and Grafe, S. (2011) Efficacy and Safety of IncobotulinumtoxinA (NT 201, Xeomin) in the Treatment of Blepharospasm—A Randomized Trial. Movement Disorders, 26, 1521-1528. [Google Scholar] [CrossRef] [PubMed]
[39] Ma, H., Qu, J., Ye, L., Shu, Y. and Qu, Q. (2021) Blepharospasm, Oromandibular Dystonia, and Meige Syndrome: Clinical and Genetic Update. Frontiers in Neurology, 12, Article ID: 630221. [Google Scholar] [CrossRef] [PubMed]
[40] Duarte, G.S., Rodrigues, F.B., Marques, R.E., Castelão, M., Ferreira, J., Sampaio, C., Moore, A.P. and Costa, J. (2020) Botulinum Toxin Type A Therapy for Blepharospasm. Cochrane Database of Systematic Reviews, 11, CD004900. [Google Scholar] [CrossRef] 
[41] Tang, M., Li, W., Ji, F., Li, X., Zhang, Y. and Liu, P. (2019) Impact of Botulinum Toxin Injections on Quality of Life and Self-Esteem in Patients with Blepharospasm. Psychology, Health & Medicine, 24, 513-518. [Google Scholar] [CrossRef] [PubMed]
[42] Tyślerowicz, M., Kiedrzyńska, W., Adamkiewicz, B., Jost, W.H. and Sławek, J. (2020) Cervical Dystonia—Improving the Effectiveness of Botulinum Toxin Therapy. Neurologia i Neurochirurgia Polska, 54, 232-242. [Google Scholar] [CrossRef] 
[43] Castelão, M., Marques, R.E., Duarte, G.S., Rodrigues, F.B., Ferreira, J., Sampaio, C., Moore, A.P. and Costa, J. (2017) Botulinum Toxin Type A Therapy for Cervical Dystonia. Cochrane Database of Systematic Reviews, 12, CD003633. [Google Scholar] [CrossRef] 
[44] Jinnah, H.A., Comella, C.L., Perlmutter, J., Lungu, C. and Hallett, M. (2018) Longitudinal Studies of Botulinum Toxin in Cervical Dystonia: Why Do Patients Discontinue Therapy? Toxicon, 147, 89-95. [Google Scholar] [CrossRef] [PubMed]
[45] Leplow, B., Eggebrecht, A. and Pohl, J. (2017) Treatment Satisfaction with Botulinum Toxin: A Comparison between Blepharospasm and Cervical Dystonia. Patient Preference and Adherence, 11, 1555-1563. [Google Scholar] [CrossRef] 
[46] Davidescu, E.I., Odajiu, I., Tulbă, D., Mitrea, I., Cucu, C. and Popescu, B.O. (2021) Psychological Traits and Behavioural Influences in Patients with Dystonia—An Observational Cohort Study in a Romanian Neurology Department. Life (Basel), 11, 612. [Google Scholar] [CrossRef] [PubMed]

为你推荐